Remifentanil in Adults With OSA

• Status: Completed
• Trial end date: 2018-05-02
• Target enrollment: 0
• Participant gender: All

Summary

Obstructive Sleep Apnea (OSA) is the most common problem that affects sleep. People with this problem have their airway blocked or minimized, causing snoring or gasping while sleeping. It can also reduce the amount of oxygen that circulates in the blood of people affected by it. Millions of Americans have OSA; 10% of adults have diagnosed OSA, an estimated 25% have undiagnosed OSA. There is concern in the medical community about how to manage pain in patients with OSA because of the risk of decreased or slower breathing associated with certain pain medications called opioids. Giving OSA patients opioids could cause them to have even lower oxygen amounts in their blood stream. It is conceivable that patients with OSA may require lower doses of opioids to cause decreased breathing as compared to patients without OSA, however this has not been proven. In this study, we are using a very short acting and easily reversible opioid pain medication called remifentanil in patients with OSA in order to find out if treated and untreated OSA patients respond to opioid differently than patients without OSA.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Washington University School of Medicine
• Treatments: Remifentanil

Criteria

Inclusion Criteria

1. 18 to 70 year-old males or non-pregnant females

2. Provide informed consent

Exclusion Criteria

1. History of liver disease

2. pregnant or nursing females

3. known history of addiction to drugs or alcohol

4. craniofacial anomalies that preclude proper fit of pupillometry goggles

5. eye abnormalities that preclude the measurement of pupil diameter

6. use of home oxygen